Khalifian Saami, Sarhane Karim A, Tammia Markus, Ibrahim Zuhaib, Mao Hai-Quan, Cooney Damon S, Shores Jaimie T, Lee W P Andrew, Brandacher Gerald
Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Ross Research Building 749D, 720 Rutland Avenue, Baltimore, MD, 21205, USA.
Arch Immunol Ther Exp (Warsz). 2015 Feb;63(1):15-30. doi: 10.1007/s00005-014-0323-9. Epub 2014 Nov 27.
Reconstructive transplantation has become a viable option to restore form and function after devastating tissue loss. Functional recovery is a key determinant of overall success and critically depends on the quality and pace of nerve regeneration. Several molecular and cell-based therapies have been postulated and tested in pre-clinical animal models to enhance nerve regeneration. Schwann cells remain the mainstay of research focus providing neurotrophic support and signaling cues for regenerating axons. Alternative cell sources such as mesenchymal stem cells and adipose-derived stromal cells have also been tested in pre-clinical animal models and in clinical trials due to their relative ease of harvest, rapid expansion in vitro, minimal immunogenicity, and capacity to integrate and survive within host tissues, thereby overcoming many of the challenges faced by culturing of human Schwann cells and nerve allografting. Induced pluripotent stem cell-derived Schwann cells are of particular interest since they can provide abundant, patient-specific autologous Schwann cells. The majority of experimental evidence on cell-based therapies, however, has been generated using stem cell-seeded nerve guides that were developed to enhance nerve regeneration across "gaps" in neural repair. Although primary end-to-end repair is the preferred method of neurorrhaphy in reconstructive transplantation, mechanistic studies elucidating the principles of cell-based therapies from nerve guidance conduits will form the foundation of further research employing stem cells in end-to-end repair of donor and recipient nerves. This review presents key components of nerve regeneration in reconstructive transplantation and highlights the pre-clinical studies that utilize stem cells to enhance nerve regeneration.
重建移植已成为在组织严重缺损后恢复形态和功能的可行选择。功能恢复是整体成功的关键决定因素,并且严重依赖于神经再生的质量和速度。已经提出了几种基于分子和细胞的疗法,并在临床前动物模型中进行了测试,以促进神经再生。雪旺细胞仍然是研究的重点,为再生轴突提供神经营养支持和信号线索。间充质干细胞和脂肪来源的基质细胞等替代细胞来源也已在临床前动物模型和临床试验中进行了测试,因为它们相对易于获取、在体外快速扩增、免疫原性最小,并且能够在宿主组织内整合和存活,从而克服了培养人雪旺细胞和神经同种异体移植所面临的许多挑战。诱导多能干细胞衍生的雪旺细胞特别受关注,因为它们可以提供大量的、患者特异性的自体雪旺细胞。然而,大多数关于基于细胞疗法的实验证据是使用接种干细胞的神经导管产生的,这些导管是为了增强神经修复中“间隙”的神经再生而开发的。尽管一期端端修复是重建移植中神经缝合的首选方法,但从神经引导导管阐明基于细胞疗法原理的机制研究将构成在供体和受体神经端端修复中进一步应用干细胞研究的基础。本综述介绍了重建移植中神经再生的关键组成部分,并重点介绍了利用干细胞促进神经再生的临床前研究。